A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab (Q44302603)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab |
scientific article |
Statements
1 reference
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab (English)
1 reference
William J Sandborn
1 reference
Brian G Feagan
1 reference
Fernando S Velayos
1 reference
James G Kahn
1 reference
26 January 2013
1 reference
1 reference
11
1 reference
6
1 reference
654-666
1 reference
Identifiers
1 reference
1 reference